- Open Access
Utilization of diagnostic ultrasound and intravenous lipid-encapsulated perfluorocarbons in non-invasive targeted cardiovascular therapeutics
Journal of Therapeutic Ultrasound volume 4, Article number: 18 (2016)
Diagnostic ultrasound (DUS) pressures have the ability to induce inertial cavitation (IC) of systemically administered microbubbles; this bioeffect has many diagnostic and therapeutic implications in cardiovascular care. Diagnostically, commercially available lipid-encapsulated perfluorocarbons (LEP) can be utilized to improve endocardial and vascular border delineation as well as assess myocardial perfusion. Therapeutically, the liquid jets induced by IC can alter endothelial function and dissolve thrombi within the immediate vicinity of the cavitating microbubbles. The cavitating LEP can also result in the localized release of any bound therapeutic substance at the site of insonation. DUS-induced IC has been tested in pre-clinical studies to determine what effect it has on acute vascular and microvascular thrombosis as well as nitric oxide (NO) release. These pre-clinical studies have consistently shown that DUS-induced IC of LEP is effective in restoring coronary vascular and microvascular flow in acute ST segment elevation myocardial infarction (STEMI), with microvascular flow improving even if upstream large vessel flow has not been achieved. The initial clinical trials examining the efficacy of short pulse duration DUS high mechanical index impulses in patients with STEMI are underway, and preliminary studies have suggested that earlier epicardial vessel recanalization can be achieved prior to arriving in the cardiac catheterization laboratory. DUS high mechanical index impulses have also been effective in pre-clinical studies for targeting DNA delivery that has restored islet cell function in type I diabetes and restored vascular flow in the extremities downstream from a peripheral vascular occlusion. Improvements in this technique will come from three dimensional arrays for therapeutic applications, more automated delivery techniques that can be applied in the field, and use of submicron-sized acoustically activated LEP droplets that may better permeate the clot prior to DUS activation and cavitation. This article will focus on these newer developments for DUS therapeutic applications.
Although diagnostic ultrasound (DUS) systems and lipid-encapsulated perfluorocarbons (LEP) like Definity (Lantheus Medical) or Sonazoid (GE Healthcare) have been approved only for imaging applications; these two products have significant therapeutic potential for non-invasive targeted thrombolysis and drug delivery. Ultrasound and microbubbles alone as a method of dissolving thrombi was first introduced in 1997  and was predicated upon work published just 1 year earlier by Tachibana and Tachibana demonstrating their potential to augment the effects of lytic therapy . Subsequent in vivo studies demonstrated that ultrasound and microbubbles alone, using low-frequency non-imaging transducers, could recanalize peripheral vascular thrombi without fibrinolytic agents [3–5]. More recently, DUS pressures, despite their short pulse duration, have proven effective at recanalizing intravascular thrombotic occlusions . The effectiveness was related to the use of intermittent high mechanical index impulses that are capable of causing both stable cavitation and inertial cavitation (IC). The intermittent application is necessary for microbubble permeation into the thrombus, and IC appears necessary, as this has been shown to create the fluid jets that erode thrombus both from outside and from within the thrombus infrastructure [6–8]. Subsequently, high mechanical index (MI) impulses from a DUS system have been used in both pre-clinical and clinical studies of acute ST segment elevation myocardial infarction (STEMI) and ischemic stroke, achieving successful coronary and cerebral recanalization with improved microvascular flow without the need of fibrinolytic therapy [9–14]. The DUS sequence has been modified slightly in each of these applications, but it is unclear how much of a modification beyond current diagnostic limits are required to achieve effective thrombolysis and targeted drug delivery. Numerous small animal studies have demonstrated the effectiveness of DUS-guided high MI impulses in targeting DNA [13–16], and more recent studies have demonstrated the potential of DUS to target the delivery of inhibitory RNA to suppress angiogenesis in adenocarcinoma [17, 18]. This review will focus on the data that has been accumulated regarding DUS efficacy in thrombolysis and drug delivery in large animals and how small modifications of current FDA-approved LEP may further improve their clinical potential.
Targeted thrombolysis with DUS
The potential for intermittent high MI impulses from a DUS transducer was first examined in a canine model of arteriovenous graft thrombosis, where intermittent high MI impulses (all <1.9 MI) were applied when low MI imaging detected microbubbles within the risk area . These high MI impulses were shown to induce IC within the graft. The addition of the high MI impulses from a DUS transducer (Acuson Sequoia 512 1.5 MHz) through a 6-cm-thick tissue-mimicking phantom improved recanalization rates from 20 to 80 % after 30 min of treatment. What was interesting in this model is that although angiographically the vessel appeared to be occluded, low MI contrast-sensitive imaging with the DUS transducer detected microbubbles channeling through the thrombus before high MI impulses were applied (Fig. 1; Additional file 1). This presence of microbubbles was also used to guide when to apply high MI impulses; the small channels that were angiographically invisible at the start of guided high MI impulses progressed to larger channels with repeated high MI impulses (Fig. 1). Furthermore, these channels opened without any adjunctive fibrinolytic, anti-thrombotic, or anti-platelet agents, suggesting that mechanical thrombus dissolution was possible in the absence of pharmacotherapy. Furthermore, no significant downstream embolization was observed with ultrasound-induced recanalization.
This study prompted subsequent investigations which examined the efficacy of DUS high MI impulses in restoring microvascular and epicardial blood flow in porcine models of acute ST segment elevation myocardial infarction, or STEMI [9–12]. These studies demonstrated that these same DUS high MI impulses were capable of restoring microvascular flow and function (Fig. 2; Additional file 2) even if epicardial recanalization was not achieved. Although epicardial recanalization rates tripled with the addition of platelet-targeted microbubbles and image-guided high MI DUS pulses, ST segment resolution (indicating microvascular recanalization) was seen with DUS high MI impulses even when epicardial recanalization was not observed, indicating that other potential mediators were playing a role in restoring microvascular flow. Subsequent studies in ischemic limb skeletal muscle downstream from a peripheral vessel ligation have confirmed that high MI DUS of LEP microbubbles can induce nitric oxide release, resulting in restoration of skeletal microvascular flow, despite persistent upstream vessel occlusion .
Slight prolongations in pulse duration on a DUS transducer may improve the amount of thrombus dissolution. By increasing pulse duration from <5 to 20 μs on a DUS transducer, a higher epicardial recanalization rate was achieved with DUS-guided therapy added to ½ dose tissue plasminogen activator. Despite the higher epicardial recanalization rate, both short and longer pulse duration high MI impulses were equally effective in ST segment resolution and improvement in wall thickening within the risk area . The guided application of 20-μs pulse duration high MI impulses during an intravenous LEP microbubble infusion, without any fibrinolytic agent, was subsequently shown to produce equivalent epicardial recanalization rates as full dose fibrinolytic therapy in subsequent randomized comparisons in this same porcine model of acute STEMI . Although this slight prolongation of pulse duration appears possible with current DUS transducers, the safety of this longer pulse duration has not been elucidated.
In an ischemic stroke, transcranial DUS and intravenous LEP microbubbles, even in the absence of tissue plasminogen activator, have recanalized intravascular and microvascular thrombi in a large porcine animal model . In this model, the DUS was modified to provide an MI of 2.4 (pulse duration <5 μs, 1.7-MHz frequency) for guided therapeutic impulses, while low MI imaging was used to guide the applications. Other larger animal models have been utilized to determine the potential for transcranial ultrasound-induced cavitation of microbubbles to reduce stroke size , but without DUS pulse durations or imaging guidance. In humans, the initial studies using a pulsed wave Doppler (PWD) and systemically administered LEP in humans with acute ischemic stroke have all combined microbubbles with full dose fibrinolytic agents [17–19]. In the presence of systemically administered LEP, PWD was successful in increasing the speed of intracranial recanalization, but did also appear to increase the risk for intracranial hemorrhage. No human trials of ischemic stroke have examined the effect of targeted ultrasound-induced cavitation alone, without fibrinolytic agents. Such trials are needed and, based on acute STEMI studies, should be done with guided intermittent application of the high MI impulses. Table 1 lists the large animal studies that have utilized DUS-targeted IC to clear thrombi in specific clinical settings.
Targeted drug and gene delivery with diagnostic ultrasound
A considerable number of small animal studies have demonstrated the ability of DUS-guided cavitation of LEP to target the delivery of DNA or RNA ([20–22]; Table 2). The delivery of DNA or short hairpin (sh) RNA can be achieved with binding of the nuclear material to cationic microbubbles. The cationic charge is achieved by altering the lipid composition of the microbubble shell. Current FDA-approved microbubbles like Definity (Lantheus Medical) do not have this charge and thus would not be expected to bind the negatively charged DNA or RNA . There are few large animal studies demonstrating the potential for DUS in this area, but one group has now published preliminary studies for DUS-guided plasmid delivery of DNA (cyclin D2/CDK4/GLP1) in diabetic baboons to target the organized regeneration of beta cells into a functionally working pancreas (Fig. 3; Additional file 3). If this can be consistently demonstrated in a large non-human primate, the potential for safe targeted gene delivery with DUS and cationic LEP in humans should be evaluated [24, 25].
The use of a commercially available LEP and DUS for targeted thrombolysis is now being tested in the first clinical trials , with promising initial results. Targeted IC of LEP has the potential not only to non-invasively and safely dissolve intravascular and microvascular thrombi but could also be effective in targeting gene delivery and has been demonstrated to target the delivery of vascular endothelial growth factors and genes for pancreatic regeneration. Diagnostic transducers have been modified in order to provide radiofrequency feedback to confirm IC has occurred, which may be necessary to confirm that a desired microbubble response has occurred .
One problem with microbubbles is that they are confined to intravascular spaces, and inertial cavitation can only increase subendothelial delivery. The LEP can also be formulated into droplets, even for the lower molecular weight fluorocarbons like octafluoropropane . Since these droplets are nanometer scale, they can cross endothelial membranes and reach interstitial spaces, which may improve targeted delivery of genes into areas of myocardial scar, and improve thrombolysis efficacy by improving clot permeation prior to acoustic activation and inertial cavitation. Studies are ongoing now to explore this new potential for DUS and LEP.
DUS, diagnostic ultrasound; IC, inertial cavitation; LEP, lipid-encapsulated perfluorocarbons; MI, mechanical index; NO, nitric oxide; PWD, pulsed wave Doppler; STEMI, ST segment elevation myocardial infarction
Porter TR, LeVeen RF, Fox R, Kricsfeld A, Xie F. Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose albumin microbubbles. Am Heart J. 1996;132(5):964–8.
Tachibana K, Tachibana S. Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation. 1995;92:1148–50.
Tsutsui JM, Xie F, Johanning J, Lof J, Cory B, He A, Thomas L, Matsunaga T, Unger E, Porter TR. Treatment of deeply located acute intravascular thrombi with therapeutic ultrasound guided by diagnostic ultrasound and intravenous microbubbles. J Ultrasound Med. 2006;25:1161–8.
Birnbaum Y, Luo H, Nagai T, Fishbein MC, Peterson TM, Li S, Kricsfeld D, Porter TR, Siegel RJ. Noninvasive in vivo clot dissolution without a thrombolytic drug: recanalization of thrombosed iliofemoral arteries by transcutaneous ultrasound combined with intravenous infusion of microbubbles. Circulation. 1998;97:130–4.
Nishioka T, Luo H, Fishbein MC, Cercek B, Forrester JS, Kim CJ, Berglund H, Siegel RJ. Dissolution of thrombotic arterial occlusion by high intensity, low frequency ultrasound and dodecafluoropentane emulsion: an in vitro and in vivo study. J Am Coll Cardiol. 1997;30:561–8.
Xie F, Lof J, Everbach C, He A, Bennett RM, Matsunaga T, Johanning J, Porter TR. Treatment of acute intravascular thrombi with diagnostic ultrasound and intravenous microbubbles. JACC Cardiovasc Imaging. 2009;2:511–8.
Miller DL. Particle gathering and microstreaming near ultrasonically activated gas-filled micropores. J Acoust Soc Am. 1988;84:1378–87.
Chen X, Leeman JE, Wang J, Pacella JJ, Villanueva FS. New insights into mechanisms of sonothrombolysis using ultra-high-speed imaging. Ultrasound Med Biol. 2014;40:258–62.
Xie F, Gao S, Wu J, Lof J, Radio S, Vignon F, Shi W, Powers J, Unger E, Everbach EC, Liu J, Porter TR. Diagnostic ultrasound induced inertial cavitation to non-invasively restore coronary and microvascular flow in acute myocardial infarction. PLoS One. 2013;8:1–7.
Wu J, Xie F, Lof J, Sayyed S, Porter TR. Utilization of modified diagnostic ultrasound and microbubbles to reduce myocardial infarct size. Heart. 2015;101:1463–7.
Xie F, Lof J, Matsunaga T, Zutshi R, Porter TR. Diagnostic ultrasound combined with glycoprotein IIb/IIa—targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation. 2009;119:1378–85.
Xie F, Slikkerveer J, Gao S, Lof J, Kamp O, Unger E, Radio S, Matsunaga T, Porter TR. Coronary and microvascular thrombolysis with guided diagnostic ultrasound and microbubbles in acute ST segment elevation myocardial infarction. J Am Soc Echocardiogr. 2011;24:1400–8.
Gao S, Zhang Y, Wu J, Shi WT, Lof J, Vignon F, Drvol L, Xie F, Muirhead D, Powers JE, High R, White ML, Porter TR. Improvements in cerebral blood flow and recanalization rates with transcranial diagnostic ultrasound and intravenous microbubbles after acute cerebral emboli. Invest Radiol. 2014;49:593–600.
Tavares B, Tsutsui J, Aguiar M, Garcia D, Oliveira M, Soeiro A, Nicolau J, Lemos P, Kali R, Porter TR, Mathias Jr W. Safety and feasibility of diagnostic ultrasound high mechanical index impulses in acute ST segment elevation myocardial infarction in humans. Am Soc Echocardiograph. 2015;28:B2. Abstract.
Belcik JT, Mott BH, Xie A, Zhao Y, Kim S, Lindner NJ, Ammi A, Linden JM, Lindner JR. Augmentation of limb perfusion and reversal of tissue ischemia produced by ultrasound-mediated microbubble cavitation. Circ Cardiovasc Imaging. 2015;8. doi:10.1161/CIRCIMAGING.114.002979.
Culp WC, Flores R, Brown AT, Lowery JD, Roberson PK, Hennings LJ, Woods SD, Hatton JH, Culp BC, Skinner RD, Borrelli MJ. Successful microbubble sonothrombolysis without tissue-type plasminogen activator in a rabbit model of acute ischemic stroke. Stroke. 2011;42:2280–5.
Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, Gonzales N, Mikulik R, Pate G, Ostrem J, Singleton W, Manvelian G, Unger EC, Grotta JC, Schellinger PD, Alexandrov AV. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol. 2009;66:28–38.
Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, Arenillas JF, Huertas R, Purroy F, Delgado P, Alvarez-Sabín J. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke. 2006;37:425–9.
Alexandrov AV, Mikulik R, Ribo M, Sharma VK, Lao AY, Tsivgoulis G, Sugg RM, Barreto A, Sierzenski P, Malkoff MD, Grotta JC. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke. 2008;39:1464–9.
Fujii H, Matkar P, Liao C, Rudenko D, Lee PJ, Kuliszewski MA, Prud’homme GJ, Leong-Poi H. Optimization of ultrasound-mediated anti-angiogenic cancer gene therapy. Mol Ther Nucleic Acids. 2013;2(October 2012), e94.
Kuliszewski MA, Kobulnik J, Lindner JR, Stewart DJ, Leong-Poi H. Vascular gene transfer of SDF-1 promotes endothelial progenitor cell engraftment and enhances angiogenesis in ischemic muscle. Mol Ther. 2011;19:895–902.
Smith AH, Kuliszewski MA, Liao C, Rudenko D, Stewart DJ, Leong-Poi H. Sustained improvement in perfusion and flow reserve after temporally separated delivery of vascular endothelial growth factor and angiopoietin-1 plasmid deoxyribonucleic acid. J Am Coll Cardiol. 2012;59:1320–8.
Unger E, Porter T, Lindner J, Grayburn P. Cardiovascular drug delivery with ultrasound and microbubbles. Adv Drug Deliv Rev. 2014;72:110–26.
Chen S, Shimoda M, Chen J, Matsumoto S, Grayburn PA. Transient overexpression of cyclin D2/CDK4/GLP1 genes induces proliferation and differentiation of adult pancreatic progenitors and mediates islet regeneration. Cell Cycle. 2012;11:695–705.
Chen S, Bastarrachea RA, Roberts BJ, Voruganti VS, Frost PA, Nava-Gonzalez EJ, Arriaga-Cazares HE, Chen J, Huang P, DeFronzo RA, Comuzzie AG, Grayburn PA. Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1. Cell Cycle. 2014;13:1145–51.
Vignon F, Shi WT, Powers JE, Everbach EC, Liu J, Gao S, Xie F, Porter TR. Microbubble cavitation imaging. IEEE Trans Ultrason Ferroelectr Freq Control. 2013;60:661–70.
Porter TR, Arena C, Sayyed S, Lof J, High RR, Xie F, Dayton PA. Targeted transthoracic acoustic activation of systemically administered nanodroplets to detect myocardial perfusion abnormalities. Circ Cardiovasc Imaging. 2015; 9. doi:10.1161/CIRCIMAGING.115.003770.
The authors want to thank Carol Gould for her dedicated work in preparing this manuscript and to the Theodore Hubbard Foundation for funding of costs associated with the manuscript preparation.
Funding from the Theodore Hubbard Foundation has helped with costs associated with the manuscript preparation.
Availability of data and supporting materials
TRP has written the entire paper, whereas FX assisted with the manuscript and table and figure preparation. SC assisted with the droplet experiments. All authors read and approved the final manuscript.
Dr. Porter has research interests in both diagnostic and therapeutic applications of perfluorocarbon droplets and microbubbles. His work includes recent publications on acoustic activation of intravenously administered droplets and use of diagnostic ultrasound-induced cavitation of systemically administered microbubbles to treat intracoronary and microvascular thrombi.
Dr. Porter receives research support from Lantheus Medical Imaging, Philips Ultrasound and Astellas Pharma Inc. From BRACCO, Dr. Porter receives educational and research support, and he is also a speaker for Lantheus Medical Imaging.
Consent for publication
Ethics approval and consent to participate
About this article
Cite this article
Porter, T.R., Choudhury, S.A. & Xie, F. Utilization of diagnostic ultrasound and intravenous lipid-encapsulated perfluorocarbons in non-invasive targeted cardiovascular therapeutics. J Ther Ultrasound 4, 18 (2016). https://doi.org/10.1186/s40349-016-0062-y
- Targeted therapy